AASLD Practice Guidance: Clinical Assessment and Management of NAFLD/MASLD

Zusammenfassung

AASLD 2023 Practice Guidelines on the Clinical Assessment and Management of Nonalcoholic Fatty Liver Disease By: Nidah S. Khakoo, M.D. @EmoryGastroHep NAFLD is a spectrum of disease, defined as a population in which ≥5% of hepatocytes display macrovascular steatosis, in the absence of alternative causes in individuals who drink little/no alcohol. •Includes nonalcoholic fatty, nonalcoholic steatohepatitis (inflammation and cellular injury with or without fibrosis) and cirrhosis(characterize

Kerninformationen

GSs 17 –18: Ultrasound (US) is not recommended to diagnose NAFLD. •US lacks sensitivity & only provides subjective quantification of steatosis. •CAP with VCTE àsuperior point-of-care technique to quantify steatosis •Alternative methods = VCTE (e.g., Fibroscan), MRE, ELF. •Can help predict an ↑...

Follow-up and reassess. Liver Biopsy if: 1.Indeterminate NITs 2.Diagnostic uncertainty 3.Persistent ↑ in AST/ALT LowRisk Intermediate OR HighRisk Suspected Cirrhosis (Clinical, imaging, or ELF >11.3) Biopsy Staging Reassess in 2-3 years Reassess annually Consider medication management ...

Fragen zu diesem Thema?

ClariMed durchsucht alle Leitlinien mit KI und liefert quellenbasierte Antworten in Sekunden.

Jetzt auf ClariMed suchen